NR3C1 and metabolic dysfunction-associated steatotic liver disease: Reductions in liver enzyme levels and the resolution of hepatic steatosis were observed, highlighting the therapeutic potential of glucocorticoid receptor antagonism in MASLD associated with hypercortisolism.